美国血栓与止血网络遗传性抗凝血酶缺乏症试点项目登记研究
美国血栓与止血网络(ATHN)12:遗传性抗凝血酶缺乏症(HAD)试点项目于2020年设计,计划纳入100例在ATHN附属中心接受治疗的HAD患者,实际纳入94例;61%发生静脉血栓栓塞(VTE),复发性血栓在抗凝治疗下仍占44.8%;女性主要危险因素是雌激素。直接口服抗凝药使用者占30%,妊娠期33%使用低分子肝素、19%产前和11%产后使用抗凝血酶浓缩物,35%的参与者接受抗凝血酶浓缩物且无不良事件。
要点
- 94例HAD患者中61%发生VTE,复发性血栓在抗凝治疗下仍占44.8%。
- 女性血栓主要危险因素为雌激素;妊娠期33%使用低分子肝素,19%产前和11%产后使用抗凝血酶浓缩物。
- 35%的参与者接受抗凝血酶浓缩物且无不良事件;直接口服抗凝药使用者占30%。
核心结论
- 在ATHN 12中,VTE是主要表现且常复发;直接口服抗凝药使用呈增加趋势;低分子肝素用于三分之一妊娠,抗凝血酶浓缩物用于五分之一妊娠且无不良事件;这些数据应鼓励前瞻性研究以优化患者管理。
研究设计与样本
- HAD登记研究于2020年设计,旨在识别100例在ATHN附属中心接受治疗的HAD患者,记录人口学、HAD类型、血栓事件、危险因素、抗凝药和抗凝血酶浓缩物使用情况;实际纳入94例患者。
主要发现
- 94例患者中65%为女性,51%为1型HAD;诊断时平均年龄26岁(SD 18岁);61%发生VTE,其中55%为深静脉血栓、27%为肺栓塞;8例发生动脉血栓。
- 复发性血栓发生于58.6%的患者(44.8%),尽管接受了抗凝治疗;女性血栓主要危险因素为雌激素。
- 直接口服抗凝药处方占30%,肝素占34%,华法林占32%;共139次妊娠,低分子肝素使用占33%,抗凝血酶浓缩物产前使用占19%、产后使用占11%;12例患者在妊娠期发生血栓。
- 79例患者接受了239次手术或操作,主要为胃肠和血管手术;总体35%的参与者接受抗凝血酶浓缩物且无不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with hereditary antithrombin deficiency (HAD) have an increased risk of venous thromboembolism (VTE). The American Thrombosis and Hemostasis Network (ATHN) 12: HAD Pilot Project established a registry to collect data on patients with HAD. OBJECTIVES: To inform current practice and serve as a platform to design a multicenter global registry for patients with HAD. METHODS: The HAD registry was designed in 2020 to identify 100 patients with HAD receiving care at ATHN-affiliated centers. Demographics, type of HAD, thrombotic events, risk factors, anticoagulants, and antithrombin (AT) concentrate administration were recorded. RESULTS: Ninety-four patients were included; 65% were females; 51% had type 1 HAD. Mean age at diagnosis was 26 years (SD, 18 years); 61% had VTE: 55% deep vein thrombosis and 27% pulmonary embolisms. Eight patients had arterial thrombosis. Recurrent thrombosis occurred in 58.6% of patients (44.8%) despite anticoagulation. The main risk factor for thrombosis in females was estrogen. Direct oral anticoagulants were prescribed in 30%, heparin in 34%, and warfarin in 32%. There were 139 pregnancies. Low-molecular-weight heparin was administered in 33% and AT concentrate in 19% and 11% prior to and after delivery, respectively. Twelve patients developed thrombosis in pregnancy. Seventy-nine patients underwent 239 surgeries or procedures, mainly gastrointestinal and vascular. Overall, 35% of participants received AT concentrate without adverse events. CONCLUSION: In ATHN 12, VTE was the predominant manifestation, frequently recurrent. There was a trend toward using direct oral anticoagulants. Low-molecular-weight heparin was administered in one-third of pregnancies and AT concentrate in one-fifth without adverse events. These data should encourage prospective studies to optimize the management of these patients.
引用
- DeSancho MT, Suvar E, Roberts JC, et al. Hereditary antithrombin deficiency pilot project registry from the American Thrombosis and Hemostasis Network. J Thromb Haemost. 2024. PMID: 39151704. doi:10.1016/j.jtha.2024.07.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。